First Oral PMPA Study Starts

May 7, 1997

Gilead Sciences announced today that they have started enrolling HIV-infected participants in a phase I/II double-blind, placebo-controlled, dose escalation trial at 3 sites that will evaluate safety, tolerability, pharmacokinetics and antiviral effect of oral PMPA. The study will examine individuals with CD4 > 199 cells and viral load > 10,000.

Initially once a day dosing will be explored at several dose levels. The goal is to establish a maximum dose that considers safety, tolerability and maximal antiviral effect. For more information about PMPA, the PMPA article recently posted on our web site discusses the data results from the first human study of PMPA which was just recently reported at a conference.